Overview: JC Virus PCR TestIntroduction: The JC Virus PCR Test detects JC virus DNA to confirm active infection, helping diagnose progressive multifocal leukoencephalopathy in immunocompromised patients. Affecting 1 in 100,000 immunocompromised individuals, PML poses diagnostic challenges due to rapid progression. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses PCR for high sensitivity, supporting virology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: JC Virus DNA Test, Active PML Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: JC virus DNA testing began in the 1990s with research by Major, who developed PCR methods. PCR advancements in the 2000s by Roche improved detection, surpassing earlier serology methods.
Purpose: Detects JC virus DNA to confirm active infection, guides supportive care, and evaluates patients with neurological decline, aiming to manage disease.
Test Parameters: JC virus DNA presence
Pretest Condition: No special preparation required. Collect CSF or whole blood. Report history of immunosuppression.
Specimen: CSF (sterile container, 1-2 mL), Whole Blood (EDTA, 3-5 mL); 1 mL CSF or 2 mL serum in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document neurological decline or immunosuppression. Include current medications or HIV status.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., brain damage), and sample collection risks.
Procedural Considerations: Uses PCR to detect DNA, requiring labs with thermal cyclers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive DNA confirms active PML, guiding care. Early management might slow progression, while untreated cases lead to death. Negative results may require MRI.
Specialist Consultation: Consult a neurologist or infectious disease specialist for interpretation.
Additional Supporting Tests: MRI, JC virus IgM, or immune status to confirm diagnosis.
Test Limitations: Specific to active infection; correlation with imaging needed. False negatives possible with low viral load.
References: CDC Guidelines, 2023; Journal of Neurovirology, Major EO, 2022.
